Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5228280 | 0.83 | KCNH2 (0.52) | KCNH2KDM4EALDH1A1 | |
| SCHEMBL5224371 | 0.82 | KCNH2 (0.44) | KCNH2P2RX7ALPLENPP3ENPP1 | |
| SCHEMBL5228191 | 0.81 | P2RX7 (0.41) | KCNH2P2RX7 | |
| SCHEMBL508179 | 0.80 | KCNH2 (0.42) | KCNH2MEN1KMT2AP2RX7ALPL | |
| SCHEMBL509432 | 0.80 | BCHE (0.40) | HTTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL5228520 | 0.80 | ALDH1A1 (0.39) | KCNH2MEN1KMT2AP2RX7ALPL | |
| SCHEMBL509008 | 0.78 | LMNA (0.38) | KCNH2MEN1KMT2AP2RX7 | |
| SCHEMBL5231467 | 0.76 | KCNH2 (0.43) | KCNH2P2RX7ALPLENPP3ENPP1 | |
| SCHEMBL509451 | 0.75 | CYP1A2 (0.45) | HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL508181 | 0.75 | KCNH2 (0.47) | HTTKCNH2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | HTT 4427/4885KCNH2 3503/4885MEN1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.